Testosterone research brings new hope for cancer patients

July 13, 2018 by Heather Gillin, Texas A&M University

Many cancer patients suffer from a loss of body mass known as cachexia. Approximately 20 percent of cancer related deaths are attributed to the syndrome of cachexia, which in cancer patients is often characterized by a rapid or severe loss of fat and skeletal muscle. Dr. Melinda Sheffield-Moore, professor and head of the Department of Health and Kinesiology, along with researchers at University of Texas Medical Branch, recently published research in the Journal of Cachexia, Sarcopenia and Muscle showing that the hormone testosterone is effective at combatting cachexia in cancer patients and improving quality of life.

These findings are important, as there are currently no established therapies targeting this loss of , and without an intervention, lose muscle function and become fatigued and weakened.

"We hoped to demonstrate these patients would go from not feeling well enough to even get out of bed to at least being able to have some basic quality of life that allows them to take care of themselves and receive therapy," Dr. Sheffield-Moore said.

Dr. Sheffield-Moore said doctors sought her expertise in nutrition and metabolism when patients were losing tremendous amounts of weight from cachexia. She said that previous nutrition-focused treatment failed to combat this severe loss of body mass, which led her team to investigate the as an option to combat the often debilitating consequences of cancer cachexia.

"We already know that testosterone builds skeletal muscle in healthy individuals, so we tried using it in a population at a high risk of muscle loss, so these patients could maintain their strength and performance status to be able to receive standard cancer therapies." Dr. Sheffield-Moore said.

During this five year National Cancer Institute funded study, patients with a type of cancer known as squamous cell carcinoma were treated with standard of care chemotherapy and/or radiation in addition to seven weeks of treatment with either testosterone or placebo. Throughout the study, patients were monitored for changes in physical activity, muscle and fat mass and tested for physical performance.

Patients in this study receiving testosterone maintained total body mass and increased lean body mass by 3.2 percent. Sustaining body mass is important considering most patients experience a 20 percent decrease in or more depending upon the type of cancer.

"Patients randomized to the group receiving testosterone as an adjuvant to their standard of care chemotherapy and/or radiation treatment also demonstrated enhanced physical activity," Dr. Sheffield-Moore said. "They felt well enough to get up and take care of some of their basic activities of daily living, like cooking, cleaning and bathing themselves."

Additionally, Dr. Sheffield-Moore's lab is currently analyzing skeletal muscle proteomic data from this study. "What the proteome [profile of proteins found in the ] tells us is which particular proteins in the skeletal muscles were either positively or negatively affected by testosterone or by cancer, respectively," Dr. Sheffield-Moore said. "It allows us to begin to dig into the potential mechanisms behind cancer cachexia."

Dr. Sheffield-Moore hopes this research will help increase quality of life and maintain eligibility to receive standard of care therapy if cachexia ensues.

Explore further: Excess zinc in muscles contributes to wasting syndrome in cancer

More information: Traver J. Wright et al, A randomized trial of adjunct testosterone for cancer-related muscle loss in men and women, Journal of Cachexia, Sarcopenia and Muscle (2018). DOI: 10.1002/jcsm.12295

Related Stories

Excess zinc in muscles contributes to wasting syndrome in cancer

June 6, 2018
It's estimated that nearly one-third of all cancer deaths are caused not by the cancer itself but by cachexia—a debilitating muscle-wasting syndrome that affects an estimated 80 percent of advanced cancer patients. Cachexia ...

Muscle growth finding may assist with cancer treatment

June 13, 2017
Monash University's Biomedicine Discovery Institute (BDI) researchers have collaboratively developed a therapeutic approach that dramatically promotes the growth of muscle mass, which could potentially prevent muscle wasting ...

Heavy lifting for cancer research

February 9, 2012
Many patients with advanced cancer suffer from cachexia, a condition also called body-wasting or wasting syndrome, which causes significant weight loss, extreme fatigue and reduces quality of life.

Cancer wasting due in part to tumor factors that block muscle repair, study shows

October 23, 2013
A new study reveals that tumors release factors into the bloodstream that inhibit the repair of damaged muscle fibers, and that this contributes to muscle loss during cancer wasting. The condition, also called cancer cachexia, ...

Uncovering the genetics of skeletal muscle growth and regeneration

March 8, 2018
Skeletal muscle has a remarkable capacity to regenerate - a capacity that is diminished in many skeletal muscle diseases and aging. To investigate the mechanism behind skeletal muscle growth and regeneration, researchers ...

Brown fat found to be at the root of cancer-related wasting syndrome

July 17, 2014
Many patients with advanced stages of cancer, AIDS, tuberculosis, and other diseases die from a condition called cachexia, which is characterized as a "wasting" syndrome that causes extreme thinness with muscle weakness. ...

Recommended for you

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

New way to target advanced breast cancers

September 20, 2018
A cytokine signature found in certain kinds of breast cancer cells can not only serve as a diagnostic tool for HER2-negative cancers but also offer an effective treatment target.

Understanding epilepsy in pediatric tumors

September 20, 2018
Pediatric brain tumors are characterized by frequent complications due to intractable epilepsy compared to adult brain tumors. However, the genetic cause of refractory epilepsy in pediatric brain cancer has not been elucidated ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.